Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

This systematic review and meta-analysis of six trials demonstrates that anti-CD38-based quadruplet regimens significantly improve progression-free and overall survival compared to triplets in transplant-ineligible myeloma patients. While quadruplets enhance MRD negativity rates, they also associate with a slight increase in severe adverse events and infections. Consequently, quadruplets are considered superior for non-frail patients.